Uso de naltrexona en la deshabituación de pacientes con dependencia de alcohol en el estado español

  1. Mercedes Izquierdo Serrano 1
  2. A. Rodríguez Martos 2
  3. J. Llopis 3
  4. B. Cañuelo 4
  5. G. Guigou 5
  6. J. Izquierdo 6
  7. A. Lorenzo 7
  8. M. Mateo 8
  9. G. Rubio 9
  10. J. Varo 10
  1. 1 Unidad de Alcoholismo.Complejo Sanitario Provincial. Plasencia.
  2. 2 Plan de Acción sobre Drogas de Barcelona
  3. 3 Unidad de Conductas Adictivas. Centro de Salud San Agustin. Castellón
  4. 4 Centro de Toxicomanias Cruz Roja. Cordoba
  5. 5 CAD Sta. Cruz de Tenerife
  6. 6 Centro Comarcal Palma Periferia. Palma de Mallorca.
  7. 7 Servicio de Psiquiatría. Hospital General de Galicia. Santiago de Compostela
  8. 8 Hospital Divino Vallés. Burgos
  9. 9 Hospital Psiquiátrico Sagrado Corazón de Jesús. Madrid
  10. 10 Centro de Salud Mental de Ermitagaña. Pamplona
Mostrar afiliacións +
Revista:
Adicciones: Revista de socidrogalcohol

ISSN: 0214-4840

Ano de publicación: 2002

Volume: 14

Número: 3

Páxinas: 327-335

Tipo: Artigo

DOI: 10.20882/ADICCIONES.488 DIALNET GOOGLE SCHOLAR lock_openAcceso aberto editor

Outras publicacións en: Adicciones: Revista de socidrogalcohol

Obxectivos de Desenvolvemento Sustentable

Resumo

Objectives: to describe the profile of alcoholic patients who most benefit from naltrexone treatment, and to show its utility in decreasing craving, relapses and consumption episodes. Methods: multicentre and observational study with a naturalistic design. 321alcohol- dependent patients (DSM-IV) treated with naltrexone were studied and followed up over 9 months. Results: the responder/ non-responder patient profile showed only differences concerning the educational level (p=0.039) and work situation (p=0.041). The outcome analysis showed the following percentages: 45.4% total abstinence or absence of alcohol consumption; 7.2% some consumption and 27.3% relapses. Discussion: It has not been possible to describe the profile of the alcoholic patient who would benefit the most from naltrexone. Limitations of the study derive from the heterogeneous sample and from the lack of a control group with random allocation of cases. More studies are needed in order to identify the predictive factors for a therapeutic response. However, this study has not only confirmed the usefulness of naltrexone in decreasing the quantity and frequency of alcohol consumption, but its long term follow-up (9 months) allowed verification of the additional benefit of a protracted treatment. After 9 months, there is also an increase in the number of patients who are able to control their consumption without fulfilling relapse criteria.

Referencias bibliográficas

  • (1) Miller, NS, Millman RB: A common cause of alcoholism. J of Substance Abuse Treatment, 41-43, 1989.
  • (2) Erickson CK. Review of neurotransmitters and their role in alcoholism treatment. Alcohol and Alcoholism 1996; 31 (suppl 1): 5-11.
  • (3) Chick J, Erickson CK. Conference summary: consensus conference on alcohol dependence and the role of pharmacotherapy in its treatment. Alcoholism: Clinical and Experimental Research 1996; 20: 391-402.
  • (4) Torres Hernández MA. Evolución tras 2 años de tratamiento de un grupo de alcohólicos. Psiquiatría Biológica 1998; 5 (supl 1): 54-60.
  • (5) Anton RF, Kranzler HR, Meyer RE. Neurobehavioral aspects of the pharmacotherapy of alcohol dependence. Clin Neuroscience 1995; 3: 145-154.
  • (6) Volpicelli JR, Ulm RR, Hopson N. Alcohol drinking in rats during and following morphine injections. Alcohol,1991; 8:289-292.
  • (7) Reid LD, Hunter GA. Morphine and naloxone modulate intake of ethanol. Alcohol,1984; 1: 33-37.
  • (8) Jiménez-Arriero, M.A; Guardia, J; Bravo de García-Quijada, JL. Características clínicas y utilización de Naltrexona en la deshabituación alcohólica: Estudio stop. Adicciones 2000; Vol.12.
  • (9) Samson HH, Doyle TF. Oral ethanol self-administration in the rat: Effect of naloxone. Pharmacol Biochem Behav, 1985; 22: 91-99.
  • (10) Volpicelli JR, Davis MA, Olgin JE. Naltrexone blocks the post-shock increase of ethanol consumption. Life Sci, 1986; 38: 841-847.
  • (11) Reid LD. Endogenous opioids and alcohol dependence: opioid alkaloids and the propensity to drink alcoholic beverages. Alcohol, 1996; 13: 5-11.
  • (12) Terenius L. Alcohol addiction (Alcoholism) and the opioid system. Alcohol, 1996; 13: 31-34.
  • (13) Volpicelli JR, Alterman AI, Hayashida M, o´Brien ChP. Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry 1992; 49: 876-880.
  • (14) O´Malley SS, Jaffe AJ, Chang G et al. Naltrexone and coping skills therapy for alcohol dependence: A controlled study. Arch Gen Psychiatry 1992; 49: 881-887.
  • (15) Volpicelli RF, Watwon NT, King AC et al. Effect of naltrexone on alcohol “high” in alcoholism. Am J Psychiatry 1995; 152: 613-615.
  • (16) Volpicelli RF, Karen LC, Watson NT, o´Brian ChP. . Effect of naltrexone in the treatment of alcoholism: Predicting response to naltrexone. J Clin Psychiatry 1995b; 56 (suppl 7): 39-44.
  • (17) O´Brian CP, Volpicelli LA, Volpicelli JR. Naltrexone in the treatment of alcoholism : A Clinical Review Alcohol 1996; 13: 35-49.
  • (18) O´Malley SS, Jaffe AJ, Rode S, Rounsaville BM. Experience of a “Slip” among alcoholics treated with naltrexone or placebo. Am J Psychiatry 1996; 153:281-283.
  • (19) O´Malley SS, Jaffe AJ, Chang G, Rode S et al. Six-month follow-up of naltrexone and psychotherapy for alcohol dependence. Arch Ge Psychiatry 1996b; 53: 217-224.
  • (20) Davidson D, Swift R, Fitz E. Naltrexone increases the latency to drink alcohol in social drinkers. Alcohol Clin Exp Res 1996; 20: 732-739.
  • (21) Rubio Valladolid, G; López Ruiz, M.:”Validación del cuestionario sobre los componentes obsesivo-compulsivo de bebida en alcohólicos españoles”. Adicciones 1999;.11 (1):7-15.
  • (22) Arias F, Ochoa E, Torres MA and GEODA Group: Predictors of response to treatment with naltrexone in alcoholism. Trastornos Adictivos 2000; 2 (3): 194-200.
  • (23) Landabaso MA, Iraurgi I, Sanz J, Fernández de Corres B, Ruíz de Apodaka J, Jiménez-Lerma JM et al.: Naltrexona más aversivo en alcohólicos refractarios a tratamiento. Psiquiat Biol 1997; 4: 5-8.
  • (24) Croop, R., Fralkner,e.,Labriola,D. The safety profile of naltrexone in the treatment of alcoholism. Results from a multicenter usage estudy. Arch. Gen. Psychiatry 1997; 54; 1130-1135.
  • (25) Torres, M.A. ;Arias, F.; Ochoa, E.: Efectividad de la naltrexona en pacientes alcohólicos. Adicciones. 2000. Vol 12. nº2. pp 49-57.
  • (26) Ochoa E, Arias F, Torres MA.: Evaluación de la seguridad del tratamiento con naltrexona en la dependencia del alcohol. Actas Esp Psiquiatr 2000; 28 (3): 161-168.
  • (27) Llopis,J.J., Rodriguez Martos, A., Gual, A.: Registro del consumo de bebidas alcohólicas mediante la unidad de bebida estándar. Diferencias geográficas. Adicciones. Vol 12, nº 1. pp 11-21.
Fonte de datos: Dialnet